Novo Nordisk Shares Are Trading Higher As GLP-1 Treatments Boost Q2 Topline, Bottom-line

Novo Nordisk A/S NVO Q2 sales increased 10% Y/Y (17% at CER) to DKK 33.04 billion.
Sales in International Operations increased 13% (17% CER) at DKK18.2 billion, and sales in North America Operations increased by 7% (16% at CER) to DKK14.8 billion.
The gross margin contracted to 83.2% from 84.1% a year ago, with the operating margin decreased from 46.1% to 44.7%.
Sales within Diabetes and Obesity care increased by 17% at CER to DKK 28.0 billion, driven by GLP-1 growth of 37% at CER, reflecting the uptake of Ozempic and Rybelsus.
In June 2021, Wegovy, semaglutide 2.4 mg, was made available to U.S. patients following the FDA's approval for weight management in adults living with obesity.
Net profit increased 14.1% Y/Y to DKK 12.1 billion, with EPS of DKK 5.26.
FY21 Outlook: Novo Nordisk expects sales growth of 10%-13% at CER (previously 6%-10%) and operating profit growth of 9-12% at CER (formerly 5-9%).
Price Action: NVO shares are up 5.60% at $97.08 during the market session on the last check Wednesday.

Earnings Calendar